Search Results

The Maryland Stem Cell Research Commission announces the release of Requests for Applications for the Maryland Stem Cell Research Fund’s first funding cycle of fiscal year 2025.

While the companies did not reveal the financial details of the deal, Novo Nordisk will provide funding for two Evotec sites in Germany and Italy to support the development of next-generation cell therapies.

The Tisch MS Research Center of New York, the world’s largest MS research center, has announced publication of the results of its FDA-approved Phase II stem cell treatment study in a leading stem cell journal, Stem Cell Research & Therapy.

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using the line for biopharmaceutical research.

The Maryland Stem Cell Research Commission is pleased to announce the next round of awards granting a total of more than $15.4 million.

Seraxis, Inc., a regenerative medicine company developing pancreatic islet replacement therapies to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, has been notified that the company is the awardee of a $400,000 Commercialization Program grant from the Maryland Stem Cell Research Fund that aims to foster Maryland research to enhance and propel stem cell treatments.

Accelerated Biosciences Corp. (“Accelerated Bio”) is excited to announce a strategic partnership with Agathos Biologics aimed at developing ethically derived cell lines from Accelerated Bio’s human Trophoblast Stem Cells (“hTSC”) for manufacturing complex biologics.

New research in the June 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights a promising approach for alleviating distress, enhancing quality of life, improving physical function, and reducing fatigue in patients with blood cancers who undergo hematopoietic stem cell transplantation.

ENCell Co., Ltd. , a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell therapy (EN001) for Charcot-Marie-Tooth disease type 1A (CMT1A) at the Peripheral Nerve Society (PNS) annual meeting in Montreal on June 23, 2024.